Journal Article

Clinical perspective of fusion inhibitors for treatment of HIV

J. K. Rockstroh and S. Mauss

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 5, pages 700-702
Published in print May 2004 | ISSN: 0305-7453
Published online May 2004 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkh161
Clinical perspective of fusion inhibitors for treatment of HIV

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

The number of antiretroviral-experienced HIV patients with multiple resistances against the currently available antiretroviral drug classes is increasing substantially. Therapeutic options for this specific group of patients are limited. The fusion inhibitor enfuvirtide represents the first new therapeutic option from a new drug class for this patient population. An optimized background therapy with remaining antiviral activity appears essential in order to avoid resistance development against enfuvirtide. Despite the high price of enfuvirtide, cost-effectiveness and increase in quality of life have been demonstrated in patients achieving virological control under optimized background and enfuvirtide therapy. In this article, the characteristics and clinical perspectives of fusion inhibitors are presented and discussed.

Keywords: Keywords: antiretroviral therapy, enfuvirtide, HAART, salvage therapy

Journal Article.  2249 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.